Search Results
- < Prev
1 of 1
- Next >
News Releases
-
May 16, 2013, 09:30 ET
The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Genomic Health Inc. (Nasdaq:GHDX), Sanofi (NYSE:SNY),...
More news about: Zacks Investment Research, Inc. , Genomic Health Inc. , Sanofi , Regeneron Pharmaceuticals, Inc. , Amgen Inc. , Isis Pharmaceuticals, Inc.
-
May 13, 2013, 07:00 ET
Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 UBS Global Healthcare Conference on Monday, May 20, 2013 at 9:00 a.m. ET in New York, NY. A live audio webcast of the presentation will...
More news about: Isis Pharmaceuticals, Inc.
-
May 09, 2013, 16:34 ET
Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that is has earned a $3.5 million milestone payment from Biogen Idec associated with the dosing of the first patient in a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA). The Phase 2 study of ISIS-SMNRx is...
More news about: Isis Pharmaceuticals, Inc.
-
May 09, 2013, 14:39 ET
Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 8:40 a.m. PT in Las Vegas, NV. A live audio webcast...
More news about: Isis Pharmaceuticals, Inc.
-
May 08, 2013, 21:50 ET
Isis Pharmaceuticals Prices Public Offering Of Common Stock
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of an underwritten public offering of 9,000,000 shares of its common stock, offered at a price to the public of $19.00 per share. The gross proceeds to Isis from this offering are expected to be $171.0 million, before...
More news about: Isis Pharmaceuticals, Inc.
-
May 07, 2013, 16:08 ET
Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer for sale 9 million shares of its common stock in an underwritten public offering. In connection with this offering, Isis intends to grant the underwriters an option to purchase an...
More news about: Isis Pharmaceuticals Inc.
-
May 07, 2013, 16:05 ET
Isis Reports Financial Results and Highlights for First Quarter 2013
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.5 million and pro forma net income of $1.2 million for the three months ended March 31, 2013 compared to a pro forma net operating loss of $16.2 million and a pro forma net loss of $21.7 million for the same...
More news about: Isis Pharmaceuticals, Inc.
-
May 06, 2013, 07:00 ET
Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 1b/2a clinical study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma (HCC). HCC is a tumor of the liver and is one of the most common cancers worldwide with at least one million...
More news about: Isis Pharmaceuticals, Inc.
-
May 02, 2013, 12:58 ET
Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' First Quarter 2013 Financial Results and Highlights Conference...
More news about: Isis Pharmaceuticals Inc.
-
Apr 23, 2013, 07:00 ET
ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA). SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of...
More news about: Isis Pharmaceuticals, Inc.
-
Apr 22, 2013, 17:13 ET
Isis Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 11:20 a.m. ET in New York, NY. A live audio webcast of the...
More news about: Isis Pharmaceuticals, Inc. , Genzyme
-
Apr 08, 2013, 09:00 ET
Roche and Isis Pharmaceuticals form alliance for Huntington's disease
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Isis Pharmaceuticals, Inc (NASDAQ: ISIS) today announced that they have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology. This alliance combines Isis' antisense expertise with...
More news about: Isis Pharmaceuticals Inc. , Roche , CHDI Foundation
-
Apr 03, 2013, 07:00 ET
Isis Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis. Apolipoprotein(a) contributes to the formation of plaque in arteries through its...
More news about: Isis Pharmaceuticals Inc.
-
Apr 01, 2013, 07:00 ET
Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the publication of new data in the journal Circulation Research [doi:10.1161/CIRCRESAHA.111.300367] demonstrating that antisense targeting of apolipoprotein C-III (apoC-III) resulted in significant reductions in apoC-III and triglycerides,...
More news about: Isis Pharmaceuticals Inc.
- < Prev
1 of 1
- Next >
Modify your Search
 |
Quickly search for PR Newswire releases by adding our plugin to your browser search |